MedTrace Logo

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

NCT05207371 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-01-26

No results posted yet for this study

Summary

Phase I Part :

Confirm the safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer, and decide recommended dose for Phase II.

Phase II Part :

Explore the efficacy and safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer at the recommended dose of GAIA-102 decided in the Phase I part.

Conditions

Interventions

BIOLOGICAL

Biological

Intravenous injection of GAIA-102 alone or with Pembrolizumab (KEYTRUDA®︎)

Sponsors & Collaborators

  • GAIA BioMedicine Inc.

    lead INDUSTRY

Principal Investigators

  • Yoshikazu Yonemitsu, MD, PhD · Graduate School of Pharmaceutical Sciences, Kyushu University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-10-01
Completion
2025-12-01

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05207371 on ClinicalTrials.gov